Whooping Cough or Pertussis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Whooping Cough or Pertussis Market Outlook

Thelansis’s “Whooping Cough or Pertussis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Whooping Cough or Pertussis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Whooping Cough or Pertussis Overview

Pertussis (commonly known as whooping cough), a respiratory infection, is caused by the gram-negative coccobacillus Bordetella pertussis and Bordetella parapertussis. The infection is spread through airborne droplets and is highly contagious, with a tendency to affect 100% of non-immune household contacts. Protection from vaccination may wane to 50% within 12 years of completion, and immunocompromised individuals may also contract Bordetella bronchiseptica, commonly known as "kennel cough." Risk factors for acquiring pertussis include pregnancy, epidemic exposure, lack of immunization, and close contact with an infected individual. The organism adheres to ciliated respiratory epithelial cells, causing local inflammatory changes in the mucosal lining and releasing toxins that act locally and systemically. Pertussis presents similarly to other respiratory infections but has a distinct progression through three phases and a persistent cough without fever. Infants and older adults have higher mortality and morbidity, respectively, with a 2% death rate in infants accounting for 96% of pertussis-related deaths. Most individuals with pertussis will recover, although the illness may last several months. Secondary complications such as pneumonia, seizures, and encephalopathy may occur. Secondary bacterial pneumonia is commonly caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Staphylococcus aureus, while viral infections include a respiratory syncytial virus, cytomegalovirus, and adenovirus may also occur.

• Worldwide, there are over 24 million cases annually, with greater than 160,000 deaths.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: